Critical Reviews™ in Therapeutic Drug Carrier Systems

ISSN for PRINT: 0743-4863

For Online Access

Best Paper Award Selection - Editorial Board Site

2003, Volume20

Issue 6

106 pages

DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i6

Issue price - $161.00

Ian R. Wilding, PhD
Pharmaceutical Profiles Ltd., Ruddington Fields, Ruddington, Nottingham, UK, NG11 6JS

David V. Prior, PhD
Pharmaceutical Profiles Ltd., Ruddington Fields, Ruddington, Nottingham, UK

The biopharmaceutical complexity of today's new drug candidates provides significant challenges for pharmaceutical scientists in terms of both candidate selection and optimizing subsequent development strategy. In addition, life cycle management of marketed drugs has become an important income stream for pharmaceutical companies, but the selection of least risk/highest benefit strategies is far from simple. The proactive adoption of human drug absorption (HDA) studies using remote controlled capsules offers the pharmaceutical scientist significant guidance for planning a route through the maze of product development. This review examines the position of HDA studies in drug development, using a variety of case histories and an insightful update on remote controlled capsules to achieve site-specific delivery.

DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i6.10 Download article, 26 pages

Article price - $40.00

  Next article >>